• By Donald Zuhn —

    USPTO Seal Last week, the U.S. Patent and Trademark Office published a notice in the Federal Register (76 Fed. Reg. 22854) proposing a number of changes to ex parte and inter partes reexamination proceedings.  In addition, the USPTO announced that it was seeking public comment regarding the proposed changes and that the Office would be holding a public meeting on June 1, 2011 to discuss the proposed changes.

    The notice indicates that the proposed changes are intended to streamline the procedures governing ex parte and inter partes reexamination proceedings, by seeking to achieve faster, more efficient resolution of the substantial new question of patentability (SNQ) for which reexamination is ordered.  While some of the proposed changes discussed in the notice impact both ex parte and inter partes reexamination proceedings, other changes are specific to either ex parte or inter partes reexamination proceedings.

    Changes impacting both ex parte and inter partes reexamination proceedings include:

    • Require requester to separately explain how each SNQ presented in the request is "new" relative to other examinations of the patent claims (rather than merely stating what the SNQ is believed to be).
    • Require requester to explain how the references apply to every limitation of every claim for which reexamination is requested.
    • Require requester to explain how multiple SNQs raised in the same request are non-cumulative of each other; cumulative SNQs will be deemed to constitute a single SNQ.
    • Permit the examiner to select one or more representative rejections from among a group of adopted rejections.
    • Limit requester's declaration and other evidence mainly to the request — new evidence may be submitted only to rebut point made in Office action or patent owner's response or statement.
    • Limit patent owner's amendments and evidence mainly to the first action response — new amendments or evidence may be submitted in response to new ground of rejection.
    • Prohibit entry of claim amendments unless accompanied by a statement explaining how the proposed new claim language renders the claims patentable in light of an SNQ.
    • Clearly define petitions practice (see table listing examples of petitions filed in reexamination proceedings on page 22858 of the Office's notice).

    Changes specific to ex parte reexamination proceedings include:

    • Make permanent the pilot procedure allowing patent owner to optionally waive patent owner's statement — the notice indicates that only about 10% of patent owners file a statement under 35 U.S.C. § 304.
    • Where the patent owner does not waive the statement, the order granting reexamination will include a provisional first Office action on the merits (FAOM), which may be made final in the next action.

    Changes specific to inter partes reexamination proceedings include:

    • Allow third party requester to dispute the examiner's designation that a rejection is "representative" of other rejections in the group.
    • Final Office action will close prosecution and trigger appeal rights.
    • Limit third party requester's appellant brief to appealing an examiner's decision that a claim is patentable; additional bases to cancel a rejected claim can only be argued in a respondent brief following patent owner's appellant brief.

    A detailed description of each proposed change can be found in the Office's notice.  In addition, the notice provides a list of thirteen questions on page 22860 for which the Office seeks comments.

    The public meeting to be held on June 1 is scheduled to begin at 1:30 pm (EST) and will be held in the South Auditorium of Madison West, 600 Dulany Street, Alexandria, VA.  Those interested in attending the meeting must register by 5:00 p.m. (EST) on May 25, 2011; those interested giving a presentation at the meeting must register by sending an e-mail to reexamimprovementcomments@uspto.gov by 5:00 p.m. (EST) on May 11, 2011.  Additional information regarding registration is provided in the notice (see page 22860 for information registrants should provide).

    Written comments regarding the proposed changes to ex parte and inter partes reexamination proceedings must be submitted by June 29, 2011.  Written comments can be submitted by e-mail to reexamimprovementcomments@uspto.gov, or mail to: Mail Stop Comments-Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313–1450, marked to the attention of Kenneth M. Schor.

  • By Donald Zuhn —

    USPTO Seal In a short, two-column notice published on Friday in the Federal Register (76 Fed. Reg. 23876), the U.S. Patent and Trademark Office reiterated that the effective date for implementation of the prioritized examination (or Track I) portion of the Enhanced Examination Timing Control Initiative has been delayed until further notice.  Under the Track I procedure, applicants can request prioritized examination at the time of filing of an application upon payment of appropriate fees ($4,000 in addition to standard filing fees) and compliance with certain requirements (as outlined in a final rule published on April 4, 2011).

    While the USPTO's April 4 notice indicated that the Patent Office would begin accepting Track I applications on May 4, 2011, USPTO Director David Kappos sent a message to Patent Office employees, notifying them that "[t]he Track One expedited patent examination program, scheduled to go into effect on May 4, 2011, is postponed until further notice" (see "USPTO News Briefs," April 21, 2011).  Since that notice, the Director has addressed the postponement on his blog and the USPTO has issued a press release regarding the postponement (see "USPTO News Briefs," April 27, 2011).

    The Office's latest notice states that "[t]he effective date for the amendments to 37 CFR 1.17 and 1.102 published at 76 FR 18399, April 4, 2011 (the Track I final rule) is delayed until further notice."  The notice indicates that a new effective date will be published in the Federal Register (at some future, unspecified date).  Most importantly, the notice states that "[n]o request for prioritized examination will be accepted until further notice."  With regard to the reason for delaying the program, the Office explains that it:

    [H]as found it necessary to revise its patent examiner hiring plan due to funding limitations.  The revised hiring plan does not permit the Office to hire new examiners.  With the current level of resources, the Office will not be able to meet the twelve-month pendency goal in prioritized examination applications without impacting the non-prioritized examination applications at this time.

    With respect to the new effective date, the Office further explains that "[w]hen the funding limitations are resolved, the Office will issue a subsequent notice identifying a revised effective date and applicability date on which the final rule shall apply."

  • By Sherri Oslick —

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Daiichi Sankyo Inc. et al. v. Watson Pharmaceuticals Inc. et al.
    1:11-cv-00345; filed April 18, 2011 in the District Court of Delaware

    • Plaintiffs:  Daiichi Sankyo Inc.; Genzyme Corp.
    • Defendants:  Watson Pharmaceuticals Inc.; Watson Pharma Inc.; Watson Laboratories Inc. (NV)

    Infringement of U.S. Patent Nos. 5,607,669 ("Amine Polymer Sequestrant and Method of Cholesterol Depletion," issued March 4, 1997) and 5,693,675 ("Alkylated Amine Polymers," issued December 2, 1997) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of plaintiffs' Welchol® (colesevelam hydrochloride, used to treat primary hyperlipidemia and type 2 diabetes mellitus).  View the complaint here.


    Abraxis Bioscience, LLC v. Kappos

    1:11-cv-00730; filed April 15, 2011 in the District Court of the District of Columbia

    Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 7,820,788 ("Compositions and Methods of Delivery of Pharmacological Agents," issued October 26, 2010).  View the complaint here.


    Allergan, Inc., et al. v. Sandoz, Inc.

    1:11-cv-00298; filed April 15, 2011 in the Middle District of North Carolina

    • Plaintiffs:  Allergan, Inc.; Duke University
    • Defendant:  Sandoz, Inc.

    Infringement of U.S. Patent Nos. 7,351,404 ("Method of Enhanced Hair Growth," issued April 1, 2008), 7,388,029 ("Compositions and Methods for Treating Hair Loss Using Non-Naturally Occurring Prostaglandins," issued June 17, 2008), and 6,403,649 (""Non-Acidic Cyclopentane Heptanoic Acid,2-Cycloalkyl Or Arylalkyl Derivatives As Therapeutic Agents, issued June 11, 2002) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Allergan's Latisse® (bimatoprost topical solution/drops, 0.03%, used to treat inadequate or not enough eye lashes).  View the complaint here.


    Celgene Corp. et al. v. Actavis South Atlantic LLC

    2:11-cv-02162; filed April 15, 2011 in the District Court of New Jersey

    • Plaintiffs:  Celgene Corp.; Novartis Pharmaceuticals Corp.; Novartis Pharma AG
    • Defendants:  Actavis South Atlantic LLC

    Infringement of U.S. Patent Nos. 5,908,850 ("Method of Treating Attention Deficit Disorders with d-Threo Methylphenidate," issued June 1, 1999), 6,355,656 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 12, 2002, with a reexamination certificate issued March 27, 2007), 6,528,530 ("Phenidate Drug Formulations Having Diminished Abuse Potential," issued March 4, 2003), 5,837,284 ("Delivery of Multiple Doses of Medications," issued November 17, 1998), 6,635,284 (same title, issued October 21, 2003), and 7,431,944 ("Delivery of Multiple Doses of Medications," issued October 7, 2008) all licensed exclusively to Novartis in certain fields of use, following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Novartis' Focalin XR® (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder).  View the complaint here.


    Abbott Laboratories et al. v. Mathilda and Terence Kennedy Institute of Rheumatology Trust

    1:11-cv-02541; filed April 13, 2011 in the Southern District of New York

    • Plaintiffs:  Abbott Laboratories; Abbott Biotechnology Ltd.
    • Defendant:  The Mathilda and Terence Kennedy Institute of Rheumatology Trust

    Declaratory judgment of invalidity of U.S. Patent No. 7,846,442 ("Methods of Treating Rheumatoid Arthritis with an Anti-TNF-Alpha Antibodies and Methotrexate," issued December 7, 2010) in conjunction with Abbott's manufacture and sale of its Humira® (adalimumab, used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis).  View the complaint here.


    Human Genome Sciences Inc. v. Genentech Inc. et al.

    1:11-cv-00328; filed April 12, 2011 in the District Court of Delaware

    • Plaintiff:  Human Genome Sciences Inc.
    • Defendants:  Genentech Inc.; City of Hope

    Declaratory judgment of invalidity, unenforceability, and non-infringement of U.S. Patent No. 7,923,221 ("Methods of Making Antibody Heavy and Light Chains Having Specificity for a Desired Antigen," issued April 12, 2011) in conjunction with HGS's manufacture and sale of its Benlysta® (belimumab, under development for the treatment of seropositive patients with systemic lupus erythematosus) product.  View the complaint here.

  • Calendar

    May 3-4, 2011 – Paragraph IV Disputes*** (American Conference Institute) – New York, NY

    May 18-19, 2011 – Forum on Freedom to Operate (C5) – Munich, Germany

    May 23-25, 2011 – 6th International Judges Conference on Intellectual Property Law (Intellectual Property Owners Association) – Brussels, Belgium

    June 2, 2011 – EPO Opposition & Appeals — The Case Law (Patent Resources Group and Management Forum) – Chicago, IL

    June 3, 2011 – European Patents — The Case Law (Patent Resources Group and Management Forum) – Chicago, IL

    June 7-8, 2011 – Biosimilars*** (American Conference Institute) – New York, NY

    June 8, 2011 – Biotechnology/Chemical/Pharmaceutical (BCP) Customer Partnership Meeting (U.S. Patent and Trademark Office) – 10:00 am – 4:00 pm (EDT)

    September 18-20, 2011 – Accelerating Intellectual Property and Innovation in South Africa (South African Department of Science and Technology) – Cape Town, South Africa

    ***Patent Docs is a media partner of this conference or CLE

  • USPTO Building Facade The U.S. Patent and Trademark Office has announced the agenda for the next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting to be held on June 8, 2011.  The proposed agenda is as follows:

    Morning Session

    • Greetings, TC Update, and Overview (10:00 – 10:30 am EDT):  Jackie Stone, George Elliott, and Remy Yucel, Directors, Technology Center 1600

    • Microsoft v. i4i Ltd.: How potential changes in the evidentiary standard for an invalidity defense could affect patent prosecution and litigation (10:30 – 11:15 am):  Garth M. Dahlen, Ph.D., Esq., Birch, Stewart, Kolasch & Birch, LLP

    • Break (11:15 – 11:30 am)

    • COPA (Clearing the Oldest Patent Applications) (11:30 am – 12:15 pm):  John Barlow, SPE, Technology Center 2800

    • Expedited Examinations (Track 1, PPH, Green Tech, AE, and to Make Special) (12:00 – 1:00 pm):  Bennett Celsa, QAS, Technology Center 1600

    • Lunch (1:00 – 2:00 pm)

    Afternoon Session

    • Current Sequence Listing Process for Nucleic Acids and Polypeptides (2:00 – 2:45 pm):  Joe Woitach, SPE, Art Unit 1633

    • Break (2:45 – 3:00 pm)

    • Common Issues Examiners Face Regarding PLTs and Plant Utility Patents (3:00 – 3:45 pm):  Anne Marie Grunberg, SPE, Art Unit 1638/1661

    • Closing Remarks/Discussion (3:45 – 4:00 pm):  Jackie Stone, George Elliott, and Remy Yucel, Directors, Technology Center 1600

    The meeting can be attended in person at the USPTO's Auditorium in Madison East, 600 Dulany Street, Alexandria, VA, or viewed online here (select the "enter as guest" option).  The Patent Office asks that non-USPTO employees login using their e-mail addresses.  Additional information regarding the BCP customer partnership meeting can be found here.

  • By James DeGiulio —

    European Union (EU) Flag In March, it appeared that patent reform leading to a unified European Union (EU) patent was on its way to being enacted, after the European Parliament pushed the latest European Commission proposal through despite a dissenting minority of member countries (see "European Parliament Approves Enhanced Cooperation Procedure to Create Unified EP Patent System").  However, this view appears to have been too optimistic, as the European Court of Justice has ruled that a separate patent court would violate European Union law by taking powers away from courts in EU countries.  The Court of Justice is primarily concerned that the proposed patent court would not have sufficient checks and balances on its power.

    The main selling point of the unified EU patent has been a reduction in costs.  While the unified EU patent would decrease application costs, the unified patent court was proposed to reduce duplicative patent litigation costs and provide a forum of specialized patent judges.  Unless the EU patent can be enforced by bringing just one suit, rather than separate suits throughout Europe, the benefit of the lower application costs may not be sufficient to warrant an overhaul of the current system.  It is not clear whether some countries will cite the lack of a single court as a reason to back out of the unified patent plan, and whether some will see the application savings as reason enough to keep supporting it.  However, without a clear patent enforcement mechanism, EU patent holders would have fewer assurances that their intellectual property is secure.

    The European Court of Justice ruling can be satisfied if the Court of Justice receives appellate jurisdiction over the new proposed unified EU patent court.  However, many are opposed to such a solution.  The Court of Justice currently has the authority to rule on EU trademark issues, and has frustrated EU attorneys by providing inconsistent rulings over the years on simple matters of trademark law.  The proposed patent court, separate from the Court of Justice, was an attempt to address that concern.  Industry representatives have made it known that they would rather maintain the current system than evoke a system where patent questions go to the Court of Justice.

    Despite the European Court of Justice ruling, the European Commission continues with its plan to create a unified EU patent, rolling out its latest proposal on April 13, noting that a unitary patent would still drastically reduce the cost of applying for patents.  However, the Commission is now weighing new ideas that comport with the Court of Justice ruling and that would meet the goals of the reform.  Most of the latest plans fail to put patent matters in front of a specialized patent court or do not solve the problem of disparate enforcement across EU countries.

    For additional information regarding this topic, please see:

    • "European Parliament Approves Enhanced Cooperation Procedure to Create Unified EP Patent System," March 1, 2011
    • "Several EU Members Push for Unified Patent System," December 30, 2010
    • "Europe Takes Step Closer to Single EU Patent and Patent Court," February 24, 2010

  •     By Donald Zuhn —

    USPTO Announces Postponement of Track 1 Examination (Again)

    USPTO Seal On April 21, USPTO Director David Kappos sent a message to Patent Office employees, notifying them that "[t]he Track One expedited patent examination program, scheduled to go into effect on May 4, 2011, is postponed until further notice."  Last Friday, the Intellectual Property Owners Association (IPO) made the text of that message available.  Director Kappos also addressed the postponement of the Track One (or prioritized examination) program on his Director's Forum blog on Friday.  Today, the USPTO issued a press release again announcing that the Track One program has been postponed.  According to the release, the program, which was scheduled to go into effect on May 4, has been postponed "until further notice due to reduced spending authority in the Full-Year Continuing Appropriations Act, 2011."  The Office noted that "[w]ithout the resources to hire a sufficient number of examiners to implement Track One, we must postpone the effective date of the program until we are in a position to implement it successfully while ensuring there will be no adverse impact on non-prioritized examination applications."  The release states that a new start date for the program will be announced "as soon as circumstances permit," and that the Office will provide the new date "via a Federal Register notice."


    USPTO Extends Patent Prosecution Highway Pilot Program with DPMA

    German Patent Office (DPMA) Last week, USPTO Director David Kappos authorized an extension of the Patent Prosecution Highway (PPH) pilot program with the German Patent and Trade Mark Office (DPMA) that was begun on April 27, 2009 (see "USPTO Begins Pilot Program with the German Patent Office").  The PPH pilot permits an applicant having an application whose claims have been allowed in the DPMA to fast track the examination of an application in the USPTO, or vice versa, such that the latter application is examined out of turn.  In particular, an applicant receiving a ruling from the USPTO (or the DPMA) that at least one claim in an application is patentable may request that the DPMA (or USPTO) fast track the examination of corresponding claims in the corresponding application in that office.  According to a notice regarding the extension of the USPTO-DPMA PPH, both offices have agreed to continue the pilot program for an additional two years to April 26, 2013, at which time it will be determined whether and how the program should be fully implemented.

    The USPTO has established PPH programs with fifteen Offices.  Currently the USPTO has PPH programs (full or pilot) in place with the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the United Kingdom Intellectual Property Office (UK IPO), the Canadian Intellectual Property Office (CIPO), IP Australia (IP AU), the European Patent Office (EPO), the Danish Patent and Trademark Office (DKPTO), the Intellectual Property Office of Singapore (IPOS), the German Patent and Trade Mark Office (DPMA), the National Board of Patents and Registration of Finland (NBPR), the Hungarian Patent Office (HPO), the Russian Federal Service for Intellectual Property, Patents and Trademarks (ROSPATENT), the Spanish Patent and Trademark Office (SPTO), the Austrian Patent Office (APO), and the Mexican Institute of Industrial Property (IMPI).


    USPTO Updates Registration Exam

    MPEP, Original Cover
    Earlier this month, the USPTO announced that it would be updating its registration examination as of April 12, 2011.  The updated exam will be based on the Manual of Patent Examining Procedure (M.P.E.P.) Edition 8, Revision 8, as well as the following materials:

    • Examination Guidelines Update: Developments in the Obviousness Inquiry after KSR v. Teleflex (75 Fed. Reg. 53643)
    (see "USPTO Updates Obviousness Examination Guidelines")

    • New Interim Patent Subject Matter Eligibility Examination Instructions (August 24, 2009 Memorandum)

    • Interim Guidance for Determining Subject Matter Eligibility for Process Claims in View of Bilski v. Kappos (75 Fed. Reg. 43922)

    • Interim Guidance for Determining Subject Matter Eligibility for Process Claims in View of Bilski v. Kappos (July 27, 2010 Memorandum)

    • Supplementary Examination Guidelines for Determining Compliance with 35 U.S.C. § 112 and for Treatment of Related Issues in Patent Applications (76 Fed. Reg. 7162)
    (see "USPTO Promulgates Guidelines for Applying 35 U.S.C. § 112, 2nd Paragraph").

  • By Donald Zuhn —

    Dow Jones Last week, Dow Jones VentureSource reported that investors put $6.4 billion of venture capital into 661 deals in the first quarter of 2011, which constituted a 35% increase in funding and a 5% increase in deals as compared with the same period last year.  VentureSource noted that corporations provided $448 million of the $6.4 billion raised by venture-backed companies and were responsible for three of the ten largest deals of the first quarter.

    Dollars & Deals
    In the healthcare sector, the VentureSource report indicated that while funding rose 21% to $1.6 billion, the number of deals dropped 6% to 148 in the first quarter of 2011 over the same period last year.  Of the industries making up the healthcare sector, biopharmaceuticals collected 53% ($849 million) of healthcare funding and was responsible for 41% (61) of the sector's deals, which constituted a 15% increase in capital and a 13% drop in deals.  The information technology sector matched the healthcare sector's $1.6 billion in funding in the first quarter.

    Earlier this month, the National Venture Capital Association (NVCA) released its own report on venture funding, which indicated that $5.9 billion had been invested in 736 deals in the first quarter (see "NVCA Reports Modest Gains in First Quarter Venture Funding").  The NVCA report also noted that $1.4 billion had been invested in 164 first quarter deals in the Life Sciences sector (which like VentureSource's healthcare sector consists primarily of biotech and medical device companies).

  • By Donald Zuhn —

    Kappos, David #1 On Friday, USPTO Director David Kappos addressed the impact of budgetary constraints on some of the Patent Office's plans for the coming year.  He did so on his Director's Forum blog, where the Director (at right) noted that following enactment of the budget for FY 2011 on April 15, the Office's total spending authority through the end of the fiscal year (i.e., September 30, 2011) had "been limited to $2.09 billion."  "Given this level of spending authority," he explained that the Office would "have to make significant reductions for the current fiscal year."  Stating that the USPTO had "not come by these decisions lightly," and that he "recognize[d] that these measures will create new challenges for our ability to carry out our agency’s mission," Director Kappos listed a number of USPTO initiatives and policies that would be postponed, suspended, or reduced "[e]ffective immediately and until further notice."

    As we noted last week, one of the programs that will be postponed is the Track 1 (or prioritized examination) portion of the Enhanced Examination Timing Control Initiative (see "USPTO News Briefs," April 21, 2011).  The opening of the USPTO satellite office in Detroit is also being postponed, "as well as consideration of other possible satellite office locations."  Office personnel will certainly feel the impact of the FY 2011 budget, with all hiring being frozen, employee training being reduced, all overtime being suspended, and "all other non-compensation-related expenses, including travel, conferences and contracts" being reduced.  In addition, the Director noted that IT projects will be "scaled back," and that funding for Patent Cooperation Treaty (PCT) outsourcing will be "substantially reduced."

    The Director's post was preceded by a somewhat more detailed e-mail message the Director sent to USPTO employees.  The Intellectual Property Owners Association (IPO) made the text of that message available on Friday.  In the e-mail, the Director notes that the Office's $2.09 billion spending limit means that the Office "will be unable to expend the additional $85-100 million in fees that we will be collecting during this fiscal year — funds that we had anticipated being able to use to fund operations this year."

    It appears that only patent operations are to be affected, as the trademark side of the Office will be "unaffected and will maintain normal operations."

    USPTO Seal In view of the budget problems highlighted in the Director's e-mail and blog post, it certainly is a case of what a difference a week — or in this case two weeks — makes.  On the heels of the December 2010 announcement of the Detroit satellite office (see "USPTO News Briefs," December 21, 2010), and the Office's indication that it was looking at other locations for satellite offices (as well as provisions in the America Invents Act that would provide for the establishment of three or more satellite offices; see "'Reform' at the U.S. Patent and Trademark Office"), several groups had begun lobbying for satellite offices in their "backyards."  On April 6, the Austin American-Statesman reported that House Judiciary Chairman Lamar Smith (R-TX) and Reps. Lloyd Doggett (D-TX), John Carter (R-TX), and Michael McCaul (R-TX) had written to Secretary of Commerce Gary Locke and Director Kappos formally asking them to consider Austin for a regional office.  The article noted that Silicon Valley had also begun a lobbying effort to secure a satellite office, and that Denver and Atlanta were considered to be contenders.  A Law360 article (subscription required) on April 14 noted that the Silicon Valley effort was in full swing, with Director Kappos meeting with IP insiders in a town hall event to discuss plans for modernizing the Patent Office.  The USPTO has posted a draft of the Director's address on its website.  While the draft does not mention satellite offices, the Law360 report notes that attendees indicated that the Director had said that Silicon Valley met several of the Office's key considerations.  However, with the spending limits imposed on he Office by the FY 2011 budget, satellite office lobbying — like satellite office consideration — is now on hold.

  • IPLAC The Intellectual Property Law Association of Chicago (IPLAC) Biotech Committee and the John Marshall Law School Center for Intellectual Property Law will offer a panel discussion entitled:  "Gene Patents . . . Statutory Subject Matter?" on April 28, 2011 from 1:00 to 2:30 PM (CDT) at the John Marshall Law School in Chicago, IL.  The panel discussion will focus on the Association for Molecular Pathology v. U.S. Patent and Trademark Office case, which was argued before the Federal Circuit on April 4, 2011.  Panelists will include Dr. Hans Sauer, Associate General Counsel for Intellectual Property for the Biotechnology Industry Organization (BIO) and Adjunct Professor of Law at the Georgetown University Law Center; Joshua D. Sarnoff, Associate Professor of Law at the DePaul University College of Law; Patent Docs author Dr. Kevin E. Noonan, Partner with McDonnell Boehnen Hulbert & Berghoff LLP and Adjunct Professor at the DePaul University College of Law and The John Marshall Law School; and Kevin Collins, Professor of Law at the Washington University School of Law.

    Myriad Patent Docs readers may recall that Dr. Sauer and Prof. Sarnoff participated in a public radio discussion of the AMP v. USPTO case back in June 2009 (see "Gene Patenting Debate Continues").  Dr. Sauer was also of counsel on BIO's amicus brief in support of reversal  (see "BIO and AUTM File Joint Amicus Brief in AMP v. USPTO").  Prof. Sarnoff, meanwhile, authored an amicus brief on behalf of the American Medical Association et al. in support of plaintiffs-appellees and affirmance.  Dr. Noonan co-authored an amicus brief for the Intellectual Property Owners Association (IPO) (see "IPO Files Amicus Brief in AMP v. USPTO"), appeared on "60 Minutes" in April 2010 to discuss the AMP v. USPTO case (see "'60 Minutes' and 'Newshour' Take Different Approaches to Covering Gene Patenting Story"), and has written extensively on gene patenting and the AMP v. USPTO case in this space.  Prof. Collins has written and presented on diagnostic method claims (see "Patenting Information").

    ACLU The registration fee for the panel discussion is $10 (students), $20 (IPLAC members), or $30 (non-IPLAC members).  IPLAC is an Accredited CLE Provider, and it is anticipated that the program will be eligible for 1.5 hours of CLE credit.  In addition, Patent Docs will be providing lunch for attendees.  Those interested in registering for the panel discussion should contact Paul Reinfelds at PREI@Lundbeck.com or Donald Zuhn at zuhn@mbhb.com to reserve a spot.